The University of Kansas Cancer Center is one of the latest major cancer research institutions to join The Leukemia & Lymphoma Society’s (LLS) Beat AML Master Clinical Trial, a paradigm-shifting collaboration to bring precision medicine to patients with acute myeloid leukemia.
A preclinical study has identified a region of the human genome, called a super-enhancer, as a novel target for a pancreatic cancer subtype.
A new, first-of-its kind project from researchers at The University of Kansas Cancer Center aims to boost participation in urologic cancer clinical trials by partnering with community urologists.
KU Cancer Center researcher Shahid Umar, PhD, is examining the microbiome's connection to colorectal cancer.
A new ultrasensitive diagnostic device invented by researchers at the University of Kansas, The University of Kansas Cancer Center and KU Medical Center could allow doctors to detect cancer quickly from a droplet of blood or plasma, leading to timelier interventions and better outcomes for patients.
Researchers at The University of Kansas Cancer Center have developed a first-of-its-kind organoid that mirrors the process of cancer spreading to the lung.
Prateek Sharma, MD, gastroenterologist and member of The University of Kansas Cancer Center, has been named president of The International Society for Diseases of the Esophagus (ISDE). The ISDE is a multidisciplinary international organization comprised of approximately 1,000 esophageal disease experts.
Dineo Khabele, MD, director of The University of Kansas Cancer Center’s gynecologic oncology division, has been elected a new member to the American Society for Clinical Investigation (ASCI) for 2019.
Steven Soper, PhD, member of The University of Kansas Cancer Center, was elected to the American Institute for Medical and Biomedical Engineering (AIMBE) College of Fellows.
The University of Kansas Cancer Center and the the Midwest Cancer Alliance co-hosted an introductory training workshop for individuals who want to learn more about KU Cancer Center’s patient research advocacy program, PIVOT
Staff at The University of Kansas Cancer Center are using a new device that makes it remarkably easy and convenient to screen for lymphedema.
Researchers work with African American and American Indian communities to identify effective tobacco cessation strategies
Physician-scientists at The University of Kansas Cancer center are designing and initiating their own clinical trials.
Triple-negative breast cancer expert Dr. Priyanka Sharma discusses latest research and clinical trial efforts.
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the treatment protocol for an invasive type of breast cancer that accounts for one-fifth of all breast cancer patients.
Researchers at The University of Kansas Cancer Center have received a five-year National Institutes of Health R0-1 grant to compare and evaluate the efficacy of optimized versus non-optimized tobacco cessation approaches for African American smokers.
Researchers at The University of Kansas Cancer Center have discovered a therapy combination that may be helpful in the treatment of certain types of ovarian cancer.
The University of Kansas Cancer Center is joining forces with a host of the nation’s top cancer centers to focus the spotlight on eliminating human papillomavirus (HPV)-related cancers in the United States.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The University of Kansas Medical Center announced that the U.S. Food and Drug Administration (FDA) has cleared it to begin a first-in-human clinical trial of MSCTC-0010 in patients with de novo high-risk acute or steroid-refractory acute graft-versus-host disease (HR/SR aGvHD).
A study conducted by researchers at The University of Kansas Cancer Center has found that early, ongoing screening of lymphatic function and immediate patient-administered therapies are highly effective in improving outcomes for women at high risk for breast cancer related lymphedema.
A new University of Kansas research effort featured in the current edition of Integrative Biology has resulted in a low-cost, reliable blood test that uses a small plastic chip about the size of a credit card that can deliver the same diagnostic information as a bone biopsy — but using a simple blood draw instead.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago. Ciclopirox Prodrug was discovered by researchers at The University of Kansas Cancer Center and KU’s Institute for Advancing Medical Innovation (IAMI).
Scott Weir, Pharm.D., Ph.D., of The University of Kansas Cancer Center, is the recipient of the 2018 Janet Davison Rowley Patient Impact Research Award. Dr. Weir serves as director of the Institute for Advancing Medical Innovation (IAMI) and as associate director for Translational Research at The University of Kansas Cancer Center.
Myers has spent the last decade researching the prevalence, possible causes, management and treatment of chemo-brain.
The University of Kansas Cancer Center was recently recognized as a “high-performing site” by the National Cancer Institute (NCI).
Researchers at The University of Kansas Cancer Center have found that mitochondrial DNA may contain information that could help determine the likelihood of cancer metastasizing.
Priyanka Sharma, M.D., a breast cancer medical oncologist at The University of Kansas Cancer Center, has been named vice chair of SWOG’s Breast Committee.
Researchers at The University of Kansas Cancer Center are working to fill the knowledge gap between DNA damage and cancer, including developing approaches to manipulate the DNA damage response to treat and prevent disease. Their research on an integral DNA repair protein was recently highlighted in the scientific journal, Nature Communications.
.The University of Kansas today announced and celebrated a five-year nearly $25 million grant from the National Institutes of Health that will fund Frontiers: University of Kansas Clinical and Translational Science Institute (KU CTSI). This grant currently is the largest at the university, and the second-largest all time.
“Roy Jensen, through his leadership and collaboration, has brought NCI (National Cancer Institute) designation to our town
.Mary Markiewicz, Ph.D., assistant professor at the University of Kansas Medical Center in the Department of Microbiology, Molecular Genetics and Immunology and a researcher with KU Cancer Center, will receive a grant, made possible by a unique partnership with the Kansas City Chiefs, ESPN, the V Foundation For Cancer Research and The University of Kansas Health System.
CicloMed LLC announced that its development candidate for non-muscle-invasive and muscle-invasive bladder cancer, Ciclopirox Prodrug, was cleared by the U.S. Food and Drug Administration to begin human clinical trials. With this clearance, CicloMed plans to initiate the first-in-human safety trial in patients with advanced solid tumor cancers as soon as possible at several centers, including The University of Kansas Cancer Center. Discovered by a multidisciplinary team of researchers at KU Cancer Center, Ciclopirox Prodrug was licensed to CicloMed LLC, a subsidiary of Kansas City-based BioNOVUS Innovations LLC, in November 2015.
Braden’s Hope announced it will be awarding $3 million to advance childhood cancer research at The University of Kansas Cancer Center and Children’s Mercy. Braden’s Hope is a Kansas City-based charity that raises awareness and funds for precision-based research to cure childhood cancers.
According to a recent study led by The University of Kansas Cancer Center researchers, a high proportion of smokers enrolled in bedside tobacco cessation programs who said they had quit were misreporting their smoking status.
The University of Kansas Cancer Center announced today that the National Cancer Institute (NCI) renewed its national cancer center designation for five years and that Children’s Mercy has been formally approved as a cancer center consortium partner
Nation's largest Powwow and health screening
New Division Director of Medical Oncology Announced
New research could make treatment for gastrointestinal cancers safer.
The University of Kansas Cancer Center and Children’s Mercy Twitter #NoTobaccoChat focused on changing the way healthcare providers treat tobacco dependence.
The University of Kansas Cancer Center joins Blood Cancer Research Partnership
On May 31, 1-2 p.m. (CDT), The University of Kansas Cancer Center and Children’s Mercy Hospital will co-host an online discussion, via Twitter, about changing the way healthcare providers treat tobacco dependence.
Latinos experience significant disparities in health care including higher rates of particular cancers, lower cancer screening rates and cancer diagnoses at more advanced stages. Researchers at The University of Kansas Cancer Center want to help Latinos with tobacco cessation treatment (both medication and behavioral support) via text messaging.
A research team comprised of members from The University of Kansas Cancer Center, Stowers Institute for Medical Research, and Children’s Mercy are looking at ways to target cancer stem cells to ensure that once a cancer patient goes into remission, they are not at risk of their cancer returning.
Researchers at The University of Kansas Cancer Center are collaborating on the “lab-on-a-chip,” a testing platform that captures and performs analysis of various biomarkers, which are actively released by tumor cells into blood. Rather than the usual invasive and costly biopsy, the credit-card size devices will screen for circulating markers that are released from cancer cells within patients’ blood.
UKanQuit, a joint inpatient program between the University of Kansas Medical Center and The University of Kansas Hospital, is helping more smokers quit the habit
A bladder cancer drug discovered and developed at The University of Kansas Cancer Center is set to become its first cancer drug to go from bench to bedside.
The University of Kansas Cancer Center and Children’s Mercy Hospital have announced four first-of-their-kind endowed chair appointments that will help eliminate childhood diseases around the world.
Researchers at The University of Kansas Cancer Center have found that high doses of drugs commonly used to fight high cholesterol can destroy a rogue protein produced by a damaged gene that is associated with nearly half of all human cancers
Statement supports shorter dosing schedule, urges action to increase national vaccination rates
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right